Resistance, Relapse in LBCL Attributed to Antigen Loss Following Axi-Cel Treatment
CD19 expression was lower in patients with large B-cell lymphoma who relapsed post-axicabtagene ciloleucel, offering an explanation for treatment resistance.
ASH 2019
High Rates of Undetectable MRD Following 2 Years of Ibrutinib-Venetoclax in Certain Patients With CLL/SLL
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
Promising Early Results for the Combination of Acalabrutinib, Obinutuzumab, and Venetoclax in Treatment-Naive CLL
An earlier study of obinutuzumab + venetoclax in combination with ibrutinib in patients with CLL showed high rates of diarrhea, bruising, and infusion-related reactions.
Promising First-Line Immunotherapy Findings in Hodgkin Lymphoma: Complete Response of 100%
The study yielded a complete response rate of 100% across 33 subjects.
Early Look at the Feasibility and Safety of a Third-Generation Anti-CD19 CAR-T Therapy
A third-generation anti-CD19 CAR-T cell therapy showed no major safety concerns and early signs of clinical activity for patients with lymphoid malignancies.
- Loading...
Loading...
Next post in ASH 2019
Loading... 
Loading...